{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.83","upperLimit":"6.54","value":"3.78"},{"groupId":"OG001","lowerLimit":"1.94","upperLimit":"3.71","value":"2.86"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"description":"Worsening is defined as a decrease in score that is at least half of standard deviation from baseline values, where standard deviation is calculated from the scores at baseline combining both treatment groups.\n\nThe EQ-5D-5L is a 5 item questionnaire that assesses 5 domains including mobility, self care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating \"health today\"","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Daratumumab subcutaneously (fixed dose of 1800 mg) or intravenously (16 mg/kg) weekly for cycles 1-2, every 2 weeks for cycles 3-6, and every 4 weeks thereafter. Pomalidomide was administered at a dose of 4 mg orally every day on days 1 through 21, and dexamethasone at 40 mg (or 20 mg for patients ≥75 years of age) orally weekly, in 28-day cycles..\n\nPomalidomide: Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.\n\nDexamethasone: Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG000","title":"Daratumumab+Pomalidomide+Dexamethasone"},{"description":"Patients received Pomalidomide at a dose of 4 mg orally every day on days 1 through 21, and dexamethasone 40 mg (or 20 mg for patients ≥75 years of age) orally weekly, in 28-day cycles","id":"OG001","title":"Pomalidomide + Dexamethasone"}],"paramType":"MEAN","populationDescription":"Intent-to-treat (ITT) analysis set: a total of 304 randomized subjects (151 in the Daratumumab/Pomalidomide/Dexamethasone group and 153 in the Pomalidomide/Dexamethasone group).","reportingStatus":"POSTED","timeFrame":"Approximately up to 3 years (assessed on Day 1 of each treatment cycle, at the end of treatment, and every 4 weeks post treatment until PD).","title":"Health-related Quality of Life-Time to Worsening in EQ-5D-5L Visual Analogue Scale","type":"SECONDARY","unitOfMeasure":"months"}